Summary
We have studied the pharmacokinetics and absolute systemic availability of indoramin (50 mg) given orally in solution or as a tablet with reference to intravenously administered drug (0.15 mg/kg) in 9 healthy volunteers.
After intravenous administration the median apparent volume of distribution was 6.3l·kg−1, plasma clearance was 20.0 ml·min−1·kg−1, and terminal half-time was 4.1 h.
When given by tablet indoramin was absorbed with moderate rapidity, with a median tmax of 1.5 h. The median systemic availability was 24%.
After oral administration in solution the drug was more rapidly absorbed, with a median tmax of 1.0 h (p<0.01). The median systemic availability was 43% (15–85%).
Plasma concentrations of an active metabolite, 6-hydroxyindoramin, after single oral doses in either dosage form, were of a similar order to those of unchanged drug and fell with similar rapidity. After intravenous administration, however, concentrations of the metabolite were negligible.
References
Bateman DN, Hobbs DC, Twomey TM, Stevens EA, Rawlins MD (1979) Prazosin: Pharmacokinetics and concentration effect. Eur J Clin Pharmacol 16: 177–181
Draffan GH, Lewis P, Firmin JL, Jordan TW, Dollery CT (1976) Pharmacokinetics of indoramin in man. Br J Clin Pharmacol 3: 489–495
Franklin RA, Robson P, Stevenson D (1983) Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man. Eur J Clin Pharmacol 24: 629–634
Johnson ES (1981) Indoramin in essential hypertension. Br J Clin Pharmacol 12: 1315–1375
Johnson G, Regårdh CG (1976) Clinical pharmacokinetics of β-adrenoceptor blocking drugs. Clin Pharmacokinet 1: 233–263
Louis WJ, Christophidis N, Brignell M, Vijayasekaran V, McNeil J, Vajda FJE (1978) Labetalol: Bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Aust NZ J Med 8: 602–609
McAllister RG, Kirsten EB (1982) The pharmacology of verapamil IV. Kinetics and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 31: 418–426
Norbury HM, Franklin RA, Marrott PK, Warrington SJ (1983) Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers. Eur J Clin Pharmacol 25: 243–246
Norbury HM, Franklin RA, Marrott PK, Warrington SJ (1984) Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers. Eur J Clin Pharmacol 27: 247–249
Pierce DM, Smith SE, Franklin RA (1986) Debrisoquine oxidation phenotype and plasma kinetics of indoramin and its metabolite 6-hydroxyindoramin. Proc. IIIrd World Conference on Clinical Pharmacology and Therapeutics (Stockholm). Acta Pharmacol Toxicol 59 [Suppl 5 (1)]: 117
Swaisland AJ (1981) Determination of therapeutic concentrations of indoramin by liquid chromatography with fluorescence detection. Analyst 106: 717–719
Volans GN, Jeffereys D, Latham AN, Frost T (1982) Pharmacokinetics of oral indoramin. Curr Med Res Opin 8: 51–53
Wartak J (1983) Clinical pharmacokinetics — A modern approach to individualised drug therapy. Praeger Publishers, New York, p 132
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pierce, D.M., Abrams, S.M.L. & Franklin, R.A. Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects. Eur J Clin Pharmacol 32, 619–623 (1987). https://doi.org/10.1007/BF02455999
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02455999